PMID- 29858711
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20190111
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 37
IP  - 9
DP  - 2018 Sep
TI  - Serological lymphocytic activity and patient-reported outcomes in Sjogren's
      syndrome.
PG  - 2361-2366
LID - 10.1007/s10067-018-4159-2 [doi]
AB  - This study was set to investigate whether serum markers of lymphocytic activity
      are associated with patient-reported outcomes in Sjogren's syndrome (SS).
      Forty-six patients with SS were included in this cross-sectional study. Patients 
      with monoclonal gammopathy, history of malignant lymphoma, or with secondary SS
      were excluded. Serum levels of IgG, beta2-microglobulin (beta2M), soluble
      interleukin-2 receptor (sIL2-R), and free light chains (FLC) were assessed.
      Systemic disease activity was measured by the EULAR SS disease activity index
      (ESSDAI). Patient-reported symptoms were recorded by visual analogue scales (VAS)
      of pain, fatigue, and dryness, as compiled in the EULAR SS patient-reported index
      (ESSPRI). Depressive symptoms were determined by the Patient Health Questionnaire
      9 (PHQ-9). Serum concentrations of kappaFLC (r = 0.491, p = 0.001), lambdaFLC (r 
      = 0.326, p = 0.027), and beta2M (r = 0.421, p = 0.004) correlated with the
      ESSDAI, whereas sIL-2R and IgG did not. No correlations between serum markers of 
      lymphocytic activity and the ESSPRI, or single VAS measures of pain, dryness, or 
      fatigue, were found. In patients with VAS fatigue scores in the upper quartile,
      sIL-2R serum levels were even decreased (p = 0.019). Only depressive symptoms as 
      determined by PHQ-9 were positively correlated with fatigue (r = 0.536, p <
      0.001). In this well-defined cohort of patients with SS, serological lymphocytic 
      activity was not correlated with patient-reported outcomes and sIL-2R levels were
      even decreased in patients with high fatigue scores. Only depressive symptoms
      were correlated with fatigue. This highlights the need to further understand the 
      link between inflammation and disease characteristics in SS.
FAU - Julich, Maike
AU  - Julich M
AD  - Department of Rheumatology and Clinical Immunology, Medical Centre - University
      of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55,
      79106, Freiburg, Germany.
FAU - Kanne, Anna-Maria
AU  - Kanne AM
AD  - Department of Rheumatology and Clinical Immunology, Medical Centre - University
      of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55,
      79106, Freiburg, Germany.
FAU - Sehnert, Bettina
AU  - Sehnert B
AD  - Department of Rheumatology and Clinical Immunology, Medical Centre - University
      of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55,
      79106, Freiburg, Germany.
FAU - Budweiser, Stephan
AU  - Budweiser S
AD  - Department of Pneumology, Rheumatology, and Nephrology, RoMed Medical Centre,
      Pettenkoferstr. 10, 83022, Rosenheim, Germany.
FAU - Voll, Reinhard E
AU  - Voll RE
AD  - Department of Rheumatology and Clinical Immunology, Medical Centre - University
      of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55,
      79106, Freiburg, Germany.
FAU - Kollert, Florian
AU  - Kollert F
AD  - Department of Rheumatology, Immunology, and Allergology, Inselspital, University 
      Hospital Bern, Freiburgerstrasse 10, 3010, Bern, Switzerland.
      florian.kollert@insel.ch.
LA  - eng
PT  - Journal Article
DEP - 20180601
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Cross-Sectional Studies
MH  - Depression/blood/psychology
MH  - Fatigue/blood/psychology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*blood
MH  - Immunoglobulin Light Chains/*blood
MH  - Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - *Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - Receptors, Interleukin-2/*blood
MH  - Severity of Illness Index
MH  - Sjogren's Syndrome/*blood/immunology/psychology
MH  - Visual Analog Scale
MH  - beta 2-Microglobulin/*blood
OTO - NOTNLM
OT  - ESSDAI
OT  - ESSPRI
OT  - FLC
OT  - Free light chains
OT  - IgG
OT  - Immunoglobulin G
OT  - PHQ-9
OT  - Sjogren's syndrome
OT  - Soluble interleukin-2 receptor
OT  - sIL-2R
OT  - beta2-microglobulin
EDAT- 2018/06/03 06:00
MHDA- 2019/01/12 06:00
CRDT- 2018/06/03 06:00
PHST- 2018/03/27 00:00 [received]
PHST- 2018/05/23 00:00 [accepted]
PHST- 2018/05/14 00:00 [revised]
PHST- 2018/06/03 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
PHST- 2018/06/03 06:00 [entrez]
AID - 10.1007/s10067-018-4159-2 [doi]
AID - 10.1007/s10067-018-4159-2 [pii]
PST - ppublish
SO  - Clin Rheumatol. 2018 Sep;37(9):2361-2366. doi: 10.1007/s10067-018-4159-2. Epub
      2018 Jun 1.